Year: 2022

DaiichiSankyo-logo-1

ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03

DaiichiSankyo-logo

ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03

ARKO-CORP-

ARKO Corp. Continues its Accretive M&A Growth Strategy and Announces Fourth Acquisition of 2022 with Agreement to Acquire Uncle’s Convenience Stores from WTG Fuels

Acquisition would expand ARKO’s Southwestern footprint in key Texas and New Mexico markets, growing store count and significantly increasing the...